CHICAGO, July 16 (Reuters) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals ABOS.O targeting a novel form of the toxic protein beta amyloid in the brain passed an early ...

Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial ...

Today’s businesses need to adapt faster than ever, global competition is fierce and, according to a recent article in the New York Times, retirement rates are accelerating. The next generation of ...

Acumen Nephrology has introduced its new practice management product, Acumen® PM, which offers a full suite of options to streamline the practice of nephrology. Following great success with its ...

SINGAPORE - The rapid growth of the biotech sector during the pandemic is creating new jobs in the field with medical technology firm Acumen Diagnostics about to add to the headcount. The company, ...